Renalytix (LSE:RENX) Change In Payables And Accrued Expense : £0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Renalytix Change In Payables And Accrued Expense?

Renalytix's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was £0.00 Mil. It means Renalytix's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Mar. 2024 .

Renalytix's Change In Payables And Accrued Expense for the fiscal year that ended in Jun. 2023 was £0.00 Mil. It means Renalytix's Accounts Payable & Accrued Expense stayed the same from Jun. 2022 to Jun. 2023 .

Renalytix Change In Payables And Accrued Expense Historical Data

The historical data trend for Renalytix's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Change In Payables And Accrued Expense Chart

Renalytix Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Renalytix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Renalytix Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £0.00 Mil.

Renalytix Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Renalytix's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Renalytix (LSE:RENX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (LSE:RENX) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

RNLX:USA RTNXF:USA 2O9:Germany

Address

5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE

Website

https://www.renalytix.com

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Renalytix (LSE:RENX) Headlines

From GuruFocus

Omnicom Health Group acquires Elsevier's Pharma Communications business in Japan, rebrands as EMC K.K.

By PRNewswire PRNewswire • 03-27-2018

Investing in Information

By Vanina Egea Vanina Egea • 03-06-2014

Paul Singer Buys Reed Elesvier

By matsandalex matsandalex • 12-14-2012

Causeway International's Top Five Holdings

By Monica Wolfe Monica Wolfe • 08-29-2013